<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790828</url>
  </required_header>
  <id_info>
    <org_study_id>B1831078</org_study_id>
    <nct_id>NCT01790828</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A</brief_title>
  <official_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha 'Registered' In Subjects With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to describe the safety and efficacy of Xyntha® during the usual care setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      non probability sample
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants by Family History of Factor VIII Inhibitor</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy (All Participants)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy in Participants Less Than (&lt;)18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy in Participants Greater Than or Equal to (≥) 18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy (All Participants)</measure>
    <time_frame>4 years</time_frame>
    <description>Response categories were excellent, good, moderate, or no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy in Participants &lt;18 Years of Age</measure>
    <time_frame>4 years</time_frame>
    <description>Response categories were excellent, good, moderate, or no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy in Participants ≥18 Years of Age</measure>
    <time_frame>4 years</time_frame>
    <description>Response categories were excellent, good, moderate, and no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Less-Than-Expected Therapeutic Effect (LETE) for On-Demand Therapy</measure>
    <time_frame>4 years</time_frame>
    <description>Less than expected therapeutic effect was defined as a 'no response' rating after each of two successive infusions less than or equl to (≤) 24 hours of on-demand therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Infusion Dose Per Bleeding for On-Demand Therapy (All Participants)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Infusion Dose Per Bleeding for On-Demand Therapy in Participants &lt;18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Infusion Dose Per Bleeding for On-Demand Therapy in Participants ≥18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Hemorrhages During Prophylaxis</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rates During Prophylaxis</measure>
    <time_frame>4 years</time_frame>
    <description>Annualized bleeding rate defined as total number of breakthrough bleeds within 48 hours (for prophylaxis purpose) divided by (/) [(total period of date of bleeding)/365.25)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With LETE Bleeds Within 48 Hours of a Preventive/Prophylaxis Dose of Xyntha</measure>
    <time_frame>4 years</time_frame>
    <description>Less than expected therapeutic effect for prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleed wtihin 48 hours of prophylaxis infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Infusion Dose During Prophylaxis (All Participants)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Infusion Dose During Prophylaxis in Participants &lt;18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Infusion Dose During Prophylaxis in Participants ≥18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Factor Consumption for On-Demand Therapy and During Prophylaxis (All Participants)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Factor Consumption for On-Demand Therapy and During Prophylaxis in Participants &lt;18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Factor Consumption for On-Demand Therapy and During Prophylaxis in Participants ≥18 Years of Age</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Xyntha group</arm_group_label>
    <description>Xyntha will be administered according to physician's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xyntha : coagulation factor IIIV (recombinant)</intervention_name>
    <description>Xyntha will be administered according to physician's discretion.</description>
    <arm_group_label>Xyntha group</arm_group_label>
    <other_name>Xyntha, MOROCTOCOG ALFA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hemophilia A
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients or legally authorized representatives of pediatric patients agree to provide
             written informed consent form (data privacy statement).

          -  Pediatric and adult patients who have been treated with Xyntha for Hemophilia A from
             first approved date by KFDA, or who are planned to be newly prescribed Xyntha.

        Exclusion Criteria:

          -  Patients with a known history of hypersensitivity to original or reformulated Xyntha
             or any component of the product.

          -  Patients with a known history of hypersensitivity to hamster protein.

          -  Patients participating in an interventional trial of any investigational drug or
             device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Rehabilitation Clinic</name>
      <address>
        <city>Guro-gu</city>
        <state>Seoul</state>
        <zip>152-834</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim Hugh Chul Internal Medicine Clinic</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>138-879</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>632-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1831078&amp;StudyName=Post%20Marketing%20Surveillance%20To%20Observe%20Safety%20And%20Efficacy%20Of%20Xyntha%AE%20In%20Subjects%20With%20Hemophilia%20A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>July 21, 2015</results_first_submitted>
  <results_first_submitted_qc>July 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2015</results_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xyntha</title>
          <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Xyntha</title>
          <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants by Family History of Factor VIII Inhibitor</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Family History of Factor VIII Inhibitor</title>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy (All Participants)</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy (All Participants)</title>
          <population>All enrolled participants; only participants who received on-demand therapy were included in the analysis.</population>
          <units>infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy in Participants Less Than (&lt;)18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants aged &lt;18 years who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy in Participants Less Than (&lt;)18 Years of Age</title>
          <population>All enrolled participants; only participants aged &lt;18 years who received on-demand therapy were included in the analysis.</population>
          <units>infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy in Participants Greater Than or Equal to (≥) 18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; participants aged ≥18 years who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Xyntha Infusions Used to Treat Each New Bleed for On-Demand Therapy in Participants Greater Than or Equal to (≥) 18 Years of Age</title>
          <population>All enrolled participants; participants aged ≥18 years who received on-demand therapy were included in the analysis.</population>
          <units>infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy (All Participants)</title>
        <description>Response categories were excellent, good, moderate, or no response.</description>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy (All Participants)</title>
          <description>Response categories were excellent, good, moderate, or no response.</description>
          <population>All enrolled participants; only participants who received on-demand therapy were included in the analysis.</population>
          <units>Number of responses</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy in Participants &lt;18 Years of Age</title>
        <description>Response categories were excellent, good, moderate, or no response.</description>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants &lt;18 years who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy in Participants &lt;18 Years of Age</title>
          <description>Response categories were excellent, good, moderate, or no response.</description>
          <population>All enrolled participants; only participants &lt;18 years who received on-demand therapy were included in the analysis.</population>
          <units>number of responses</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy in Participants ≥18 Years of Age</title>
        <description>Response categories were excellent, good, moderate, and no response.</description>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants ≥18 years who receive don-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responses by Type of Response for All Xyntha Infusions for Treatment of a Bleed for On-Demand Therapy in Participants ≥18 Years of Age</title>
          <description>Response categories were excellent, good, moderate, and no response.</description>
          <population>All enrolled participants; only participants ≥18 years who receive don-demand therapy were included in the analysis.</population>
          <units>number of responses</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Less-Than-Expected Therapeutic Effect (LETE) for On-Demand Therapy</title>
        <description>Less than expected therapeutic effect was defined as a 'no response' rating after each of two successive infusions less than or equl to (≤) 24 hours of on-demand therapy.</description>
        <time_frame>4 years</time_frame>
        <population>Data were not analyzed as no participants experienced rating of 'no response'.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Less-Than-Expected Therapeutic Effect (LETE) for On-Demand Therapy</title>
          <description>Less than expected therapeutic effect was defined as a 'no response' rating after each of two successive infusions less than or equl to (≤) 24 hours of on-demand therapy.</description>
          <population>Data were not analyzed as no participants experienced rating of 'no response'.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Infusion Dose Per Bleeding for On-Demand Therapy (All Participants)</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Infusion Dose Per Bleeding for On-Demand Therapy (All Participants)</title>
          <population>All enrolled participants; only participants who received on-demand therapy were included in the analysis.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1997.00" spread="892.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Infusion Dose Per Bleeding for On-Demand Therapy in Participants &lt;18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants &lt;18 years who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Infusion Dose Per Bleeding for On-Demand Therapy in Participants &lt;18 Years of Age</title>
          <population>All enrolled participants; only participants &lt;18 years who received on-demand therapy were included in the analysis.</population>
          <units>IU</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="725.00" spread="892.77" lower_limit="725.00" upper_limit="725.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Infusion Dose Per Bleeding for On-Demand Therapy in Participants ≥18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants ≥18 years who received on-demand therapy were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Infusion Dose Per Bleeding for On-Demand Therapy in Participants ≥18 Years of Age</title>
          <population>All enrolled participants; only participants ≥18 years who received on-demand therapy were included in the analysis.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2315.00" spread="623.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Hemorrhages During Prophylaxis</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; n (number) equals (=) number of participants with nonmissing values</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Hemorrhages During Prophylaxis</title>
          <population>All enrolled participants; n (number) equals (=) number of participants with nonmissing values</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All participants (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants &lt;18 years (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants ≥18 years (n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleeding Rates During Prophylaxis</title>
        <description>Annualized bleeding rate defined as total number of breakthrough bleeds within 48 hours (for prophylaxis purpose) divided by (/) [(total period of date of bleeding)/365.25)]</description>
        <time_frame>4 years</time_frame>
        <population>Data were not analyzed as information on breakthrough bleeds within 48 hours was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleeding Rates During Prophylaxis</title>
          <description>Annualized bleeding rate defined as total number of breakthrough bleeds within 48 hours (for prophylaxis purpose) divided by (/) [(total period of date of bleeding)/365.25)]</description>
          <population>Data were not analyzed as information on breakthrough bleeds within 48 hours was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With LETE Bleeds Within 48 Hours of a Preventive/Prophylaxis Dose of Xyntha</title>
        <description>Less than expected therapeutic effect for prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleed wtihin 48 hours of prophylaxis infusion.</description>
        <time_frame>4 years</time_frame>
        <population>Data were not analyzed as information on breakthrough bleeds within 48 hours was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With LETE Bleeds Within 48 Hours of a Preventive/Prophylaxis Dose of Xyntha</title>
          <description>Less than expected therapeutic effect for prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleed wtihin 48 hours of prophylaxis infusion.</description>
          <population>Data were not analyzed as information on breakthrough bleeds within 48 hours was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Infusion Dose During Prophylaxis (All Participants)</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants with nonmissing data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Infusion Dose During Prophylaxis (All Participants)</title>
          <population>All enrolled participants; only participants with nonmissing data were included in the analysis.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1926.70" spread="532.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Infusion Dose During Prophylaxis in Participants &lt;18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants &lt;18 years were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Infusion Dose During Prophylaxis in Participants &lt;18 Years of Age</title>
          <population>All enrolled participants; only participants &lt;18 years were included in the analysis.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1243.75" spread="894.51" lower_limit="725.00" upper_limit="725.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Infusion Dose During Prophylaxis in Participants ≥18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants ≥18 years with nonmissing data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Infusion Dose During Prophylaxis in Participants ≥18 Years of Age</title>
          <population>All enrolled participants; only participants ≥18 years with nonmissing data were included in the analysis.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2000.16" spread="437.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Factor Consumption for On-Demand Therapy and During Prophylaxis (All Participants)</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; participants were excluded from the analysis if total number of infusions for prophylaxis was unknown.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Factor Consumption for On-Demand Therapy and During Prophylaxis (All Participants)</title>
          <population>All enrolled participants; participants were excluded from the analysis if total number of infusions for prophylaxis was unknown.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66371.00" spread="60985.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Factor Consumption for On-Demand Therapy and During Prophylaxis in Participants &lt;18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants &lt;18 years were included in the analysis and participants were excluded from the analysis if total number of infusions for prophylaxis was unknown.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Factor Consumption for On-Demand Therapy and During Prophylaxis in Participants &lt;18 Years of Age</title>
          <population>All enrolled participants; only participants &lt;18 years were included in the analysis and participants were excluded from the analysis if total number of infusions for prophylaxis was unknown.</population>
          <units>IU</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2900.00" spread="894.51" lower_limit="2900.00" upper_limit="2900.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Factor Consumption for On-Demand Therapy and During Prophylaxis in Participants ≥18 Years of Age</title>
        <time_frame>4 years</time_frame>
        <population>All enrolled participants; only participants ≥18 years were included in the analysis; participants were excluded from the analysis if total number of infusions for prophylaxis was unknown.</population>
        <group_list>
          <group group_id="O1">
            <title>Xyntha</title>
            <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Factor Consumption for On-Demand Therapy and During Prophylaxis in Participants ≥18 Years of Age</title>
          <population>All enrolled participants; only participants ≥18 years were included in the analysis; participants were excluded from the analysis if total number of infusions for prophylaxis was unknown.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70104.59" spread="60704.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to 6 months after the first administration of Xyntha.</time_frame>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another subject, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Xyntha</title>
          <description>Non-interventional, observational study of participants who were prescribed and received at least 1 dose of Xyntha 250, 500, 1000, or 2000 IU.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>WHOART v092</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dermatitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

